BLADDER
Important biomarkers and testing to know about
FGFR2/FGFR3, PD-L1
FGFR alterations can open targeted-treatment discussions; PD-L1 may help frame immunotherapy decisions in some settings.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
BRAIN
Important biomarkers and testing to know about
IDH, MGMT, 1p/19q, BRAF, TERT
For primary brain tumors, the exact diagnosis matters. These markers can help classify the tumor, estimate behavior, and sometimes guide treatment.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
BREAST
Important biomarkers and testing to know about
ER, PR, HER2, BRCA1/2, PALB2, PD-L1, MSI/TMB, NTRK
Hormone receptors and HER2 are foundational. In metastatic disease, inherited and tumor testing may also uncover targeted, immunotherapy, or trial options.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
CERVICAL
Important biomarkers and testing to know about
PD-L1 CPS, MSI/MMR, TMB, HER2; selected tumors: NTRK and other actionable alterations
These results may affect immunotherapy, targeted-treatment, or clinical-trial discussions, especially after progression.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
COLORECTAL
Important biomarkers and testing to know about
KRAS/NRAS, BRAF V600E, MSI/MMR, HER2, NTRK; broader profiling may identify additional targets
RAS, BRAF and MSI/MMR are especially important because they can directly change treatment choices. HER2 and rare fusions may add additional options.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
ESOPHAGEAL
Important biomarkers and testing to know about
HER2, PD-L1 CPS, MSI/MMR; broader profiling may include NTRK and other actionable alterations
HER2, PD-L1 and MSI/MMR can influence systemic-treatment choices; broader profiling may identify targeted or trial options.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
GIST
Important biomarkers and testing to know about
KIT, PDGFRA, SDH; selected cases: BRAF, NTRK
GIST is driven by biology. Mutation testing can be critical because the specific driver can determine which targeted medicines are most appropriate.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
LIVER
Important biomarkers and testing to know about
AFP; tumor profiling may include MSI/MMR, NTRK and other actionable alterations when appropriate
AFP is an important HCC marker, while broader molecular testing can sometimes identify uncommon treatment or trial opportunities.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
LUNG
Important biomarkers and testing to know about
EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK, HER2, PD-L1
Comprehensive testing before treatment is especially important in metastatic non-small cell lung cancer because multiple findings have matched targeted therapies.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
MELANOMA
Important biomarkers and testing to know about
BRAF V600, NRAS, KIT; selected cases: NTRK, MSI/TMB
BRAF status can directly affect targeted-treatment options. Tumor type and site can determine whether additional testing is useful.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
NEUROENDOCRINE
Important biomarkers and testing to know about
Tumor grade/Ki-67, somatostatin receptor (SSTR) status; selected tumors: MSI/MMR, RET, NTRK
Grade and SSTR status can strongly shape treatment planning, including whether somatostatin-receptor-directed treatment may be relevant.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
OVARIAN
Important biomarkers and testing to know about
BRCA1/2, HRD; broader profiling may include MSI/MMR and other actionable findings
BRCA and HRD testing can influence PARP-inhibitor discussions and should include consideration of both tumor and inherited testing.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
PANCREATIC
Important biomarkers and testing to know about
BRCA1/2, PALB2, MSI/MMR, NTRK; comprehensive profiling may reveal KRAS subtype and other rare targets
Inherited testing and tumor profiling can uncover treatment choices that standard pathology alone may miss.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
PROSTATE
Important biomarkers and testing to know about
BRCA1/2 and other homologous-recombination repair genes, MSI/MMR; PSMA expression for PSMA-directed therapy
Genomic testing and PSMA assessment can open targeted, immunotherapy, radioligand, or trial discussions in advanced disease.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.
RENAL CELL / KIDNEY
Important biomarkers and testing to know about
Tumor subtype first; selected profiling may include VHL, MET, FH/SDH and other alterations
Kidney cancer is not one disease. Histologic subtype and inherited-risk clues often determine which molecular tests are most useful.
Not every test applies to every person. Your cancer subtype, prior treatment, tumor tissue and current clinical situation help determine what should be tested and when.